{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:49:52Z","timestamp":1785858592608,"version":"3.56.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,27]]},"DOI":"10.1097\/01.tp.0000173770.42403.f7","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T04:01:03Z","timestamp":1128571263000},"page":"749-758","source":"Crossref","is-referenced-by-count":113,"title":["Low Incidence of Malignancy among Sirolimus\/Cyclosporine-Treated Renal Transplant Recipients"],"prefix":"10.1097","volume":"80","author":[{"given":"Barry D.","family":"Kahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarkin K.","family":"Yakupoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deijan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.","family":"Van Buren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210129","first-page":"876","article-title":"Cancers in cyclosporine-treated vs azathioprine-treated patients.","volume":"28","author":"Penn","year":"1996","journal-title":"Transplant Proc"},{"key":"R2-7-20210129","first-page":"1383","article-title":"De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation.","volume":"25","author":"Sheil","year":"1993","journal-title":"Transplant Proc"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(95)92780-8","article-title":"Risk of neoplasia in renal transplant patients.","volume":"346","author":"London","year":"1995","journal-title":"Lancet"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","article-title":"Post-transplant malignancy: the role of immunosuppression.","volume":"23","author":"Penn","year":"2000","journal-title":"Drug Saf"},{"key":"R5-7-20210129","first-page":"210","article-title":"Development and incidence of cancer following cyclosporine therapy.","volume":"18","author":"Penn","year":"1986","journal-title":"Transplant Proc"},{"key":"R6-7-20210129","first-page":"353","article-title":"A multivariate analysis of discharge immunosuppression and post-transplant malignancy [abstract 868].","volume":"1","author":"Cherikh","year":"2001","journal-title":"Am J Transplant"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporine regimens.","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/00007890-200212270-00017","article-title":"Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?","volume":"74","author":"Vivarelli","year":"2002","journal-title":"Transplantation"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00838048","article-title":"The role of immunosuppression in lymphoma formation.","volume":"20","author":"Penn","year":"1998","journal-title":"Springer Semin Immunopathol"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism.","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials of the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation.","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplant Proc"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1432-2277.2003.tb00287.x","article-title":"Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.","volume":"16","author":"Garcia","year":"2003","journal-title":"Transpl Int"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","article-title":"Conversion to sirolimus: a successful treatment for posttransplantation Kaposi\u2019s sarcoma.","volume":"77","author":"Campistol","year":"2004","journal-title":"Transplantation"},{"key":"R17-7-20210129","first-page":"145","article-title":"Clinical Transplants 2000.","author":"Kahan","year":"2001"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0041-1345(00)02473-8","article-title":"Sirolimus permits steroid withdrawal from a cyclosporine regimen.","volume":"33","author":"Mahalati","year":"2001","journal-title":"Transplant Proc"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/clinchem\/42.8.1294","article-title":"Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period.","volume":"42","author":"Amante","year":"1996","journal-title":"Clin Chem"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/00007890-199810270-00013","article-title":"Immunosuppressive effects and safety of a sirolimus\/cyclosporine combination regimen for renal transplantation.","volume":"66","author":"Kahan","year":"1998","journal-title":"Transplantation"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial.","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. For the Rapamune U.S. Study Group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/clinchem\/42.12.1943","article-title":"Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection.","volume":"42","author":"Napoli","year":"1996","journal-title":"Clin Chem"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/S0041-1345(03)00351-8","article-title":"Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience.","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplant Proc"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.7164\/antibiotics.37.1231","article-title":"Activity of rapamycin (AY-22,989) against transplanted tumors.","volume":"37","author":"Eng","year":"1984","journal-title":"J Antibiot (Tokyo)"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4615-1809-9_5","article-title":"Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.","volume":"1","author":"Wiederrecht","year":"1995","journal-title":"Prog Cell Cycle Res"},{"key":"R29-7-20210129","first-page":"886","article-title":"Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.","volume":"59","author":"Hosoi","year":"1999","journal-title":"Cancer Res"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1128\/MCB.22.23.8184-8198.2002","article-title":"Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.","volume":"22","author":"Law","year":"2002","journal-title":"Mol Cell Biol"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/mol.54.5.815","article-title":"Studies on the mechanism of resistance to rapamycin in human cancer cells.","volume":"54","author":"Hosoi","year":"1998","journal-title":"Mol Pharmacol"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Rapamycin for Kaposi\u2019s sarcoma in renal transplant patients.","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.V91.2.561","article-title":"The upregulation of p 27kipl by rapamycin results in G1 arrest in exponentially growing T-cell lines.","volume":"92","author":"Kawamata","year":"1998","journal-title":"Blood"},{"key":"R34-7-20210129","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/32433","article-title":"A causal role for E-cadherin in the transition from adenoma to carcinoma.","volume":"392","author":"Perl","year":"1998","journal-title":"Nature"},{"key":"R35-7-20210129","first-page":"297","article-title":"Maintenance immunosuppression with TOR inhibitors is associated with a reduced incidence of de novo malignancies [abstract 505].","volume":"4","author":"Kauffman","year":"2004","journal-title":"Am J Transplant"},{"key":"R36-7-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/00007890-199910270-00024","article-title":"Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group.","volume":"68","author":"Pirsch","year":"1999","journal-title":"Transplantation"},{"key":"R37-7-20210129","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-7-20210129","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0041-1345(98)01992-7","article-title":"Cancer risk associated with ATG\/OKT3 in renal transplantation.","volume":"31","author":"Hibberd","year":"1999","journal-title":"Transplant Proc"},{"key":"R39-7-20210129","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJM199012203232502","article-title":"Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.","volume":"323","author":"Swinnen","year":"1990","journal-title":"N Engl J Med"},{"key":"R40-7-20210129","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00007890-199559040-00006","article-title":"Primary kidney tumors before and after renal transplantation.","volume":"59","author":"Penn","year":"1995","journal-title":"Transplantation"},{"key":"R41-7-20210129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00005392-199707000-00012","article-title":"Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients.","volume":"158","author":"Doublet","year":"1997","journal-title":"J Urol"},{"key":"R42-7-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"R43-7-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/ajkd.2000.8290","article-title":"Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients.","volume":"36","author":"Ramsay","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R44-7-20210129","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/ajkd.2003.50130","article-title":"Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia.","volume":"41","author":"Carroll","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.TP.0000173770.42403.F7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:55:44Z","timestamp":1785855344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200509270-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,27]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000173770.42403.f7","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9,27]]}}}